Imaging of Effector Memory T Cells during a Delayed-Type Hypersensitivity Reaction and Suppression by Kv1.3 Channel Block

Immunity

Volumn 29, Issue 4, 2008, Pages 602-614

  Matheu, Melanie P ^a   Beeton, Christine ^a   Garcia, Adriana ^a   Chi, Victor ^a   Rangaraju, Srikant ^a   Safrina, Olga ^a   Monaghan, Kevin ^a   Uemura, Marc I ^a   Li, Dan ^b   Pal, Sukumar ^b   de la Maza, Luis M ^b   Monuki, Edwin ^b   Flügel, Alexander ^c   Pennington, Michael W ^d   Parker, Ian ^a   Chandy, K George ^a   Cahalan, Michael D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^d Bachem Holding AG   (Switzerland)

Author keywords

CELLIMMUNO; MOLIMMUNO

Indexed keywords

AUTACOID; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR7; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOTOXIN; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.3; SHK 186; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL ENLARGEMENT; CELL MOTILITY; CHLAMYDIA; CHLAMYDIASIS; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; EFFECTOR CELL; ENZYME INHIBITION; EXPERIMENTAL INFECTION; FEMALE; FLUORESCENCE MICROSCOPY; HELPER CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INFLUENZA; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION; TARGET CELL; TH1 CELL;

ANIMALS; ANTIGEN-PRESENTING CELLS; CELL MOVEMENT; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COLLAGEN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HYPERSENSITIVITY, DELAYED; IMMUNOLOGIC MEMORY; KV1.3 POTASSIUM CHANNEL; LYMPH NODES; LYMPHOCYTE ACTIVATION; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; OVALBUMIN; POTASSIUM CHANNEL BLOCKERS; PROTEINS; RATS; RATS, INBRED LEW; RECEPTORS, CCR7; T-LYMPHOCYTES;

EID: 53349102834     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immuni.2008.07.015     Document Type: Article

References (49)

1. Andreasen S.O., Thomsen A.R., Koteliansky V.E., Novobrantseva T.I., Sprague A.G., de Fougerolles A.R., and Christensen J.P. Expression and functional importance of collagen-binding integrins, alpha 1 beta 1 and alpha 2 beta 1, on virus-activated T cells. J. Immunol. 171 (2003) 2804-2811
2. Azam P., Sankaranarayanan A., Homerick D., Griffey S., and Wulff H. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J. Invest. Dermatol. 127 (2007) 1419-1429
3. Beeton C., and Chandy K.G. Induction and monitoring of adoptive delayed type hypersensitivity in rats. J. Visualized Experiments 8 (2007) 10.3791/325 Published online October 1, 2007
4. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad. Sci. USA 98 (2001) 13942-13947
5. Beeton C., Pennington M.W., Wulff H., Singh S., Nugent D., Crossley G., Khaytin I., Calabresi P.A., Chen C.Y., Gutman G.A., and Chandy K.G. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol. Pharmacol. 67 (2005) 1369-1381
6. Beeton C., Wulff H., Standifer N.E., Azam P., Mullen K.M., Pennington M.W., Kolski-Andreaco A., Wei E., Grino A., Counts D.R., et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. USA 103 (2006) 17414-17419
7. + channels as targets for specific immunomodulation. Trends Pharmacol. Sci. 25 (2004) 280-289
8. Conrad C., Boyman O., Tonel G., Tun-Kyi A., Laggner U., de Fougerolles A., Kotelianski V., Gardner H., and Nestle F.O. alpha(1)beta(1) integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat. Med. 13 (2007) 836-842
9. de Fougerolles A.R., Sprague A.G., Nickerson-Nutter C.L., Chi-Rosso G., Rennert P.D., Gardner H., Gotwals P.J., Lobb R.R., and Koteliansky V.E. Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis. J. Clin. Invest. 105 (2000) 721-729
10. Dustin M.L., and de Fougerolles A.R. Reprogramming T cells: The role of extracellular matrix in coordination of T cell activation and migration. Curr. Opin. Immunol. 13 (2001) 286-290
11. Ellis C.N., and Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 345 (2001) 248-255
12. Fanger C.M., Rauer H., Neben A.L., Miller M.J., Wulff H., Rosa J.C., Ganellin C.R., Chandy K.G., and Cahalan M.D. Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. J. Biol. Chem. 276 (2001) 12249-12256
13. Ferguson T.A., Mizutani H., and Kupper T.S. Two integrin-binding peptides abrogate T cell-mediated immune responses in vivo. Proc. Natl. Acad. Sci. USA 88 (1991) 8072-8076
14. + T lymphocytes: Green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses. Nat. Med. 5 (1999) 843-847
15. Gaga M., Frew A.J., Varney V.A., and Kay A.B. Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase skin reactions and classical delayed-type hypersensitivity. J. Immunol. 147 (1991) 816-822
16. Goffe B., Papp K., Gratton D., Krueger G.G., Darif M., Lee S., Bozic C., Sweetser M.T., and Ticho B. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin. Ther. 27 (2005) 1912-1921
17. Gomez M., Luque A., del Pozo M.A., Hogg N., Sanchez-Madrid F., and Cabanas C. Functional relevance during lymphocyte migration and cellular localization of activated beta1 integrins. Eur. J. Immunol. 27 (1997) 8-16
18. + T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study. J. Am. Acad. Dermatol. 49 (2003) 816-825
19. + T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls. J. Neuroimmunol. 183 (2007) 168-174
20. Hancock W.W., Khoury S.J., Carpenter C.B., and Sayegh M.H. Differential effects of oral versus intrathymic administration of polymorphic major histocompatibility complex class II peptides on mononuclear and endothelial cell activation and cytokine expression during a delayed-type hypersensitivity response. Am. J. Pathol. 144 (1994) 1149-1158
21. Heydtmann M., Hardie D., Shields P.L., Faint J., Buckley C.D., Campbell J.J., Salmon M., and Adams D.H. Detailed analysis of intrahepatic CD8 T cells in the normal and hepatitis C-infected liver reveals differences in specific populations of memory cells with distinct homing phenotypes. J. Immunol. 177 (2006) 729-738
22. + T lymphocytes. J. Immunol. 179 (2007) 4563-4570
23. Kawakami N., Nagerl U.V., Odoardi F., Bonhoeffer T., Wekerle H., and Flugel A. Live imaging of effector cell trafficking and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesion. J. Exp. Med. 201 (2005) 1805-1814
24. Kivisakk P., Mahad D.J., Callahan M.K., Sikora K., Trebst C., Tucky B., Wujek J., Ravid R., Staugaitis S.M., Lassmann H., and Ransohoff R.M. Expression of CCR7 in multiple sclerosis: Implications for CNS immunity. Ann. Neurol. 55 (2004) 627-638
25. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. USA 102 (2005) 9571-9576
26. + memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. J. Neuroimmunol. 181 (2006) 157-164
27. + and opening of voltage-gated potassium channels activate T cell integrin function: Physical and functional association between Kv1.3 channels and beta1 integrins. J. Exp. Med. 191 (2000) 1167-1176
28. Li Y.Y., Perez H.D., and Zollner T.M. Fatalities in natalizumab treatment-a 'no go' for leukocyte recirculation approaches?. Expert Opin. Ther. Targets 10 (2006) 489-499
29. Lim Y.C., Wakelin M.W., Henault L., Goetz D.J., Yednock T., Cabanas C., Sanchez-Madrid F., Lichtman A.H., and Luscinskas F.W. Alpha4beta1-integrin activation is necessary for high-efficiency T-cell subset interactions with VCAM-1 under flow. Microcirculation 7 (2000) 201-214
30. Luque A., Gomez M., Puzon W., Takada Y., Sanchez-Madrid F., and Cabanas C. Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain. J. Biol. Chem. 271 (1996) 11067-11075
31. Mackay C.R., Marston W.L., Dudler L., Spertini O., Tedder T.F., and Hein W.R. Tissue-specific migration pathways by phenotypically distinct subpopulations of memory T cells. Eur. J. Immunol. 22 (1992) 887-895
32. Matheu M.P., Deane J.A., Parker I., Fruman D.A., and Cahalan M.D. Class IA phosphoinositide 3-kinase modulates basal lymphocyte motility in the lymph node. J. Immunol. 179 (2007) 2261-2269
33. Miller M.J., Wei S.H., Parker I., and Cahalan M.D. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science 296 (2002) 1869-1873
34. Negulescu P.A., Shastri N., and Cahalan M.D. Intracellular calcium dependence of gene expression in single T lymphocytes. Proc. Natl. Acad. Sci. USA 91 (1994) 2873-2877
35. Negulescu P.A., Krasieva T.B., Khan A., Kerschbaum H.H., and Cahalan M.D. Polarity of T cell shape, motility, and sensitivity to antigen. Immunity 4 (1996) 421-430
36. 2+ imaging. Cell Calcium 30 (2001) 383-393
37. Panyi G., Vamosi G., Bacso Z., Bagdany M., Bodnar A., Varga Z., Gaspar R., Matyus L., and Damjanovich S. Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. Proc. Natl. Acad. Sci. USA 101 (2004) 1285-1290
38. Pereira L.E., Villinger F., Wulff H., Sankaranarayanan A., Raman G., and Ansari A.A. Pharmacokinetics, toxicity, and functional studies of the selective kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp. Biol. Med. (Maywood) 232 (2007) 1338-1354
39. Picker L.J., Terstappen L.W., Rott L.S., Streeter P.R., Stein H., and Butcher E.C. Differential expression of homing-associated adhesion molecules by T cell subsets in man. J. Immunol. 145 (1990) 3247-3255
40. Rosen H., Sanna M.G., Cahalan S.M., and Gonzalez-Cabrera P.J. Tipping the gatekeeper: S1P regulation of endothelial barrier function. Trends Immunol. 28 (2007) 102-107
41. Rowin M.E., Whatley R.E., Yednock T., and Bohnsack J.F. Intracellular calcium requirements for beta1 integrin activation. J. Cell. Physiol. 175 (1998) 193-202
42. Rus H., Pardo C.A., Hu L., Darrah E., Cudrici C., Niculescu T., Niculescu F., Mullen K.M., Allie R., Guo L., et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc. Natl. Acad. Sci. USA 102 (2005) 11094-11099
43. Sallusto F., Geginat J., and Lanzavecchia A. Central memory and effector memory T cell subsets: Function, generation, and maintenance. Annu. Rev. Immunol. 22 (2004) 745-763
44. Schmitz A., Sankaranarayanan A., Azam P., Schmidt-Lassen K., Homerick D., Hansel W., and Wulff H. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol. Pharmacol. 68 (2005) 1254-1270
45. Soler D., Humphreys T.L., Spinola S.M., and Campbell J.J. CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood 101 (2003) 1677-1682
46. + T lymphocytes produce multiple cytokines and proliferate in vivo in humans. J. Immunol. 177 (2006) 8185-8190
47. Szabo S.J., Sullivan B.M., Peng S.L., and Glimcher L.H. Molecular mechanisms regulating Th1 immune responses. Annu. Rev. Immunol. 21 (2003) 713-758
48. Wulff H., Beeton C., and Chandy K.G. Potassium channels as therapeutic targets for autoimmune disorders. Curr. Opin. Drug Discov. Devel. 6 (2003) 640-647
49. + channel in effector memory T cells as new target for MS. J. Clin. Invest. 111 (2003) 1703-1713